S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up. (14th February 2019)

• Record Type: Journal Article
• Authors: Lang, Berenice M.; Balermpas, Panagiotis; Bauer, Andrea; Blum, Andreas; Brölsch, G. Felix; Dirschka, Thomas; Follmann, Markus; Frank, Jorge; Frerich, Bernhard; Fritz, Klaus; Hauschild, Axel; Heindl, Ludwig M.; Howaldt, Hans‐Peter; Ihrler, Stephan; Kakkassery, Vinodh; Klumpp, Bernhard; Krause‐Bergmann, Albrecht; Löser, Christoph; Meissner, Markus; Sachse, Michael M.; Schlaak, Max; Schön, Michael P.; Tischendorf, Lutz; Tronnier, Michael; Vordermark, Dirk; Welzel, Julia; Weichenthal, Michael; Wiegand, Susanne; Kaufmann, Roland; Grabbe, Stephan
• Is Part Of: Journal der Deutschen Dermatologischen Gesellschaft. Volume 17:Number 2(2019)
• Page Start: 214
• Page End: 230
• Publication Date: 2019-02-14
• Subjects: Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5005
• DOI: 10.1111/ddg.13755
• Languages: English
• ISSNs: 1610-0379

Abstract

Summary: Basal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.